We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Artivion Secures FDA Approval for NEXUS Aortic Arch System
Read MoreHide Full Article
Key Takeaways
AORT gained 5.3% after the FDA approved its NEXUS Aortic Arch System for treating complex aortic disease.
Approval allows Artivion to potentially acquire Endospan, backed by a $150M loan for financing.
NEXUS showed strong TRIOMPHE trial results, including 90% survival and 98% freedom from reintervention.
Artivion, Inc. (AORT - Free Report) recently announced that the FDA has approved the premarket approval application for the NEXUS Aortic Arch System. Developed in partnership with Endospan Ltd., this innovative device targets aortic arch disease, one of the most challenging areas in cardiovascular care.
The FDA approval gives Artivion the right to exercise its option to acquire Endospan Ltd. within a 90-day window from the date of approval. In preparation for this possibility, the company has secured a $150 million delayed draw term loan to help finance the potential acquisition.
Per management, the earlier-than-expected FDA approval of NEXUS is a major and encouraging development for patients with aortic arch disease, as well as for Endospan and Artivion. Results from the TRIOMPHE trial have highlighted the technology’s strong clinical benefits and expressed pride in AORT’s role in supporting Endospan throughout the process. The company has arranged financing to enable a potential acquisition and is working through its decision on exercising that option, with plans to share updates with shareholders in the near future.
Likely Trend of AORT Stock Following the News
Following the announcement, AORT shares gained 5.3% at yesterday’s closing. In the year-to-date period, shares of the company have dropped 22.8% compared with the industry’s 15% decline and the S&P 500’s 4.1% fall.
In the long run, the FDA approval of NEXUS is a transformative catalyst as it allows AORT to address an underserved patient population with a minimally invasive solution and strengthens its position in the high-growth aortic repair market. Strong clinical results enhance credibility, accelerate adoption among physicians and boost shareholder confidence. The potential acquisition of Endospan Ltd. could provide full ownership of the technology, improve the margin profile and accelerate commercialization efforts.
AORT currently has a market capitalization of $1.62 billion.
Image Source: Zacks Investment Research
More on the News
The NEXUS system is a branched endovascular stent graft designed to treat conditions such as chronic aortic dissections without the need for traditional open-chest surgery. Historically, patients with aortic arch disease had limited options, often facing highly invasive procedures with significant risks. This approval marks a meaningful shift toward safer, less invasive interventions for high-risk patients.
Clinical data from the TRIOMPHE IDE trial underscores the system’s potential impact. At one year post-treatment, the device demonstrated 90% survival from lesion-related death, 90% freedom from disabling stroke and an impressive 98% freedom from reintervention due to endoleaks. These outcomes are notable given the complexity and risk profile of the patient population involved.
Overall, the FDA approval of the NEXUS system not only strengthens Artivion’s position in the cardiovascular device market but also represents a major advancement in patient care, offering hope to individuals who had limited and high-risk treatment options.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the cardiovascular devices market is valued at $80.61 billion in 2026 and is expected to witness a CAGR of 7.8% through 2035.
Factors such as the rising global burden of cardiovascular diseases, a growing geriatric population, continuous technological advancements — including AI integration, remote monitoring and minimally invasive solutions — and increased investments in research and clinical trials are enhancing market expansions.
Some better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% for 2026 compared with the industry’s 14.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Artivion Secures FDA Approval for NEXUS Aortic Arch System
Key Takeaways
Artivion, Inc. (AORT - Free Report) recently announced that the FDA has approved the premarket approval application for the NEXUS Aortic Arch System. Developed in partnership with Endospan Ltd., this innovative device targets aortic arch disease, one of the most challenging areas in cardiovascular care.
The FDA approval gives Artivion the right to exercise its option to acquire Endospan Ltd. within a 90-day window from the date of approval. In preparation for this possibility, the company has secured a $150 million delayed draw term loan to help finance the potential acquisition.
Per management, the earlier-than-expected FDA approval of NEXUS is a major and encouraging development for patients with aortic arch disease, as well as for Endospan and Artivion. Results from the TRIOMPHE trial have highlighted the technology’s strong clinical benefits and expressed pride in AORT’s role in supporting Endospan throughout the process. The company has arranged financing to enable a potential acquisition and is working through its decision on exercising that option, with plans to share updates with shareholders in the near future.
Likely Trend of AORT Stock Following the News
Following the announcement, AORT shares gained 5.3% at yesterday’s closing. In the year-to-date period, shares of the company have dropped 22.8% compared with the industry’s 15% decline and the S&P 500’s 4.1% fall.
In the long run, the FDA approval of NEXUS is a transformative catalyst as it allows AORT to address an underserved patient population with a minimally invasive solution and strengthens its position in the high-growth aortic repair market. Strong clinical results enhance credibility, accelerate adoption among physicians and boost shareholder confidence. The potential acquisition of Endospan Ltd. could provide full ownership of the technology, improve the margin profile and accelerate commercialization efforts.
AORT currently has a market capitalization of $1.62 billion.
Image Source: Zacks Investment Research
More on the News
The NEXUS system is a branched endovascular stent graft designed to treat conditions such as chronic aortic dissections without the need for traditional open-chest surgery. Historically, patients with aortic arch disease had limited options, often facing highly invasive procedures with significant risks. This approval marks a meaningful shift toward safer, less invasive interventions for high-risk patients.
Clinical data from the TRIOMPHE IDE trial underscores the system’s potential impact. At one year post-treatment, the device demonstrated 90% survival from lesion-related death, 90% freedom from disabling stroke and an impressive 98% freedom from reintervention due to endoleaks. These outcomes are notable given the complexity and risk profile of the patient population involved.
Overall, the FDA approval of the NEXUS system not only strengthens Artivion’s position in the cardiovascular device market but also represents a major advancement in patient care, offering hope to individuals who had limited and high-risk treatment options.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the cardiovascular devices market is valued at $80.61 billion in 2026 and is expected to witness a CAGR of 7.8% through 2035.
Factors such as the rising global burden of cardiovascular diseases, a growing geriatric population, continuous technological advancements — including AI integration, remote monitoring and minimally invasive solutions — and increased investments in research and clinical trials are enhancing market expansions.
Artivion, Inc. Price
Artivion, Inc. price | Artivion, Inc. Quote
AORT’s Zacks Rank & Key Picks
Currently, AORT carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% for 2026 compared with the industry’s 14.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.